152.81
2.19 (1.45%)
Penutupan Terdahulu | 150.62 |
Buka | 150.42 |
Jumlah Dagangan | 434,220 |
Purata Dagangan (3B) | 617,018 |
Modal Pasaran | 8,580,067,328 |
Harga / Pendapatan (P/E Ke hadapan) | 74.63 |
Harga / Jualan (P/S) | 10.62 |
Harga / Buku (P/B) | 3.49 |
Julat 52 Minggu | |
Tarikh Pendapatan | 29 Apr 2025 - 5 May 2025 |
Margin Keuntungan | -3.53% |
Margin Operasi (TTM) | 5.59% |
EPS Cair (TTM) | -0.420 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 10.40% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | 76.90% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 34.44% |
Nisbah Semasa (MRQ) | 6.79 |
Aliran Tunai Operasi (OCF TTM) | 145.69 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 183.66 M |
Pulangan Atas Aset (ROA TTM) | 0.92% |
Pulangan Atas Ekuiti (ROE TTM) | -1.16% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Medical Instruments & Supplies (US) | Menurun | Bercampur |
Medical Instruments & Supplies (Global) | Menurun | Menurun | |
Stok | Repligen Corporation | Menaik | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 1.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -0.5 |
Purata | 1.13 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
|
Sektor | Healthcare |
Industri | Medical Instruments & Supplies |
Gaya Pelaburan | Small Core |
% Dimiliki oleh Orang Dalam | 6.44% |
% Dimiliki oleh Institusi | 106.05% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 190.00 (JP Morgan, 24.34%) | Beli |
Median | 180.00 (17.79%) | |
Rendah | 150.00 (Canaccord Genuity, -1.84%) | Pegang |
Purata | 172.80 (13.08%) | |
Jumlah | 3 Beli, 2 Pegang | |
Harga Purata @ Panggilan | 138.96 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 05 May 2025 | 180.00 (17.79%) | Beli | 140.92 |
RBC Capital | 30 Apr 2025 | 189.00 (23.68%) | Beli | 137.99 |
JP Morgan | 29 Apr 2025 | 190.00 (24.34%) | Beli | 139.43 |
Canaccord Genuity | 16 Apr 2025 | 150.00 (-1.84%) | Pegang | 132.10 |
Evercore ISI Group | 18 Mar 2025 | 155.00 (1.43%) | Pegang | 144.34 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
22 May 2025 | Pengumuman | Repligen Corporation to Present at William Blair Growth Conference |
07 May 2025 | Pengumuman | Repligen Corporation to Present at Upcoming May Investor Conferences |
29 Apr 2025 | Pengumuman | Repligen Reports First Quarter 2025 Financial Results |
15 Apr 2025 | Pengumuman | Repligen to Report First Quarter 2025 Financial Results |
08 Apr 2025 | Pengumuman | Repligen Appoints Jacob Johnson As Vice President Investor Relations |
04 Mar 2025 | Pengumuman | Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices |
04 Mar 2025 | Pengumuman | Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |